Identification of B-Cell Epitopes for Eliciting Neutralizing Antibodies against the SARS-CoV-2 Spike Protein through Bioinformatics and Monoclonal Antibody Targeting
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global public health crisis. Effective COVID-19 vaccines developed by Pfizer-BioNTech, Moderna, and Astra Zeneca have made significant impacts in controlling the COVID-19 burden, especially in reducing the transmission of SARS...
Main Authors: | Hui Xuan Lim, Malihe Masomian, Kanwal Khalid, Asqwin Uthaya Kumar, Paul A. MacAry, Chit Laa Poh |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-04-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/23/8/4341 |
Similar Items
-
Comirnaty-Elicited and Convalescent Sera Recognize Different Spike Epitopes
by: Sascha Hein, et al.
Published: (2021-12-01) -
Rabbit Monoclonal Antibody Specifically Recognizing a Linear Epitope in the RBD of SARS-CoV-2 Spike Protein
by: Junping Hong, et al.
Published: (2021-07-01) -
Identification of conserved linear epitopes in the SARS-CoV-2 receptor-binding region using monoclonal antibodies
by: Yujie Yang, et al.
Published: (2023-06-01) -
Antibodies Targeting Two Epitopes in SARS-CoV-2 Neutralize Pseudoviruses with the Spike Proteins from Different Variants
by: Chee-Hing Yang, et al.
Published: (2021-07-01) -
New Monoclonal Antibodies Specific for Different Epitopes of the Spike Protein of SARS-CoV-2 and Its Major Variants: Additional Tools for a More Specific COVID-19 Diagnosis
by: Sabrina Mariotti, et al.
Published: (2023-02-01)